Innate Pharma will focus R&D on monoclonal antibodies

03/6/2010 | Reuters

Innate Pharma said it will concentrate on the development of monoclonal antibodies while halting the development of some experimental drugs, including IPH 1101 for the indication of chronic blood cancer and two RNA-based drug candidates. "The [RNA candidate] projects will not be binned, but we will try to find buyers to continue them," said Laure-Helene Mercier, head of the firm's investor relations.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR